<DOC>
	<DOCNO>NCT01985373</DOCNO>
	<brief_summary>Intravenous immunoglobulin ( IVIG ) use treatment heterogeneous group immune relate disorder immune-replacement immune-modulating therapy . Sanquin develop 100 mg/ml IVIg product ( Nanogam 100 mg/ml ) . Patient receive one infusion Nanogam 50 mg/ml use ( dose ) subsequently 4 infusion Nanogam 100 mg/ml ( dose ) . Aim show bioequivalency 50 mg/ml 100 mg/ml product Sanquin .</brief_summary>
	<brief_title>Pharmacokinetics Safety IVIG Nanogam 100 mg/ml</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Primary hypogammaglobulinemia , particularly patient XLA CVID Stabilised treatment Nanogam 50 mg/ml 24 week interval hospital home willing treat 1 infusion Nanogam 50 mg/ml 4 infusion Nanogam 100 mg/ml hospital A stable clinical situation ( activity disease ; stable immunoglobulin dose frequency ) Age &gt; = 18 year The patient sign consent form Known allergic reaction human plasma plasma product Having ongoing progressive disease , include HIV infection Pregnancy lactation Known insufficiency coronary cerebral circulation Having renal insufficiency ( plasma creatinin &gt; 115Âµmol/L ) Having IgA deficiency antiIgA antibody detect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>intravenous immunoglobulin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>10 % IVIG</keyword>
</DOC>